SEC Filing Summary
Issuer mismatch: The request identifies Bio Green Med Solution, Inc., but the supplied Form 10-Q is for Cyclacel Pharmaceuticals, Inc. This summary reflects the filing provided, not the named company.
Business context and reporting period
Quarterly report for the three months ended March 31, 2022; financial statements are unaudited. Cyclacel is a clinical-stage biopharmaceutical company developing cancer therapies. Its principal programs are fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor. The company reported no revenue in either Q1 2022 or Q1 2021.
Key financial metrics
| Metric | Q1 2022 / March 31, 2022 | Prior comparable period / December 31, 2021 |
|---|---|---|
| Revenue | $0 | $0 in Q1 2021 |
| Research and development expense | $4.954 million | $2.566 million in Q1 2021 |
| General and administrative expense | $1.605 million | $1.739 million in Q1 2021 |
| Operating loss | $6.559 million | $4.305 million in Q1 2021 |
| Net loss | $4.108 million | $3.478 million in Q1 2021 |
| Net loss applicable to common shareholders | $4.158 million; $0.42 per share | $3.528 million; $0.50 per share in Q1 2021 |
| Operating cash used | $6.775 million | $3.566 million in Q1 2021 |
| Cash and cash equivalents | $29.639 million | $36.559 million at Dec. 31, 2021 |
| Working capital | $30.373 million | $47.691 million at March 31, 2021 |
| Total liabilities | $6.219 million | $5.324 million at Dec. 31, 2021 |
There is no meaningful revenue-based margin to assess. The filing reports no conventional borrowings; liabilities were primarily payables, accruals and a $15,000 lease liability. Accumulated deficit was $389.1 million. Cash declined by $6.920 million during the quarter. Working-capital figures include non-cash current assets, including research and development tax-credit receivables.
Material changes versus the prior period
- R&D expense rose 93% year over year, mainly from greater fadraciclib trial activity and clinical-trial site costs for CYC140. Fadraciclib R&D expense increased to $3.645 million from $1.662 million; CYC140 expense increased to $1.122 million from $679,000.
- G&A expense declined 8%, attributed to lower professional and recruitment costs.
- Q1 2022 included $1.280 million of other income, primarily royalty income under a legacy asset-purchase agreement with Thermo Fisher. This compares with $126,000 in Q1 2021 and is not a predictable operating revenue stream.
- Cash used in operations increased by $3.209 million year over year, reflecting a larger loss and working-capital movements. Q1 2021 financing included approximately $18.0 million from an equity offering and warrant exercises; there were no comparable capital-raising proceeds in Q1 2022.
Outlook, commentary and risks
- Management said the $29.6 million of cash at March 31, 2022 was expected to fund operating expenses and capital requirements through June 30, 2023, and stated that substantial doubt about going concern was not raised for at least one year from issuance. Funding beyond that period depends on raising additional capital.
- Management expected 2022 R&D expense to increase from 2021 as clinical programs advance; G&A expense was expected to decline slightly. The company did not anticipate revenue for the foreseeable future.
- Management warned that additional funding may not be available on acceptable terms, or at all. If funding is unavailable, the company may delay, reduce or discontinue trials or R&D, change its operating plan, or partner programs earlier than planned.
- COVID-19-related supply-chain pressures and clinical-trial enrollment or logistics disruptions, as well as geopolitical turmoil, could affect costs, trial progress and access to capital. The company said the full impact was uncertain.
- At the filing date, 13 patients had been treated in the fadraciclib solid-tumor/lymphoma study and three in the hematological-malignancy study. The first patient in the CYC140 hematological-malignancy study was dosed in April 2022.
- Q1 comprehensive loss was $4.183 million. Foreign-currency translation and intercompany-loan movements substantially offset in other comprehensive income/loss.
- The Board approved, subject to stockholder approval, a proposed 500,000-share increase to the 2018 Equity Incentive Plan. The company also reported a $10 million at-the-market sales agreement; approximately $4.0 million gross had been sold through March 31, 2022.
Most important facts to verify
- Confirm the intended issuer: the supplied filing is Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc.
- Verify the cash runway assumptions and the timing and availability of future financing, including the expected June 30, 2023 funding horizon.
- Assess the clinical-trial pace, enrollment, safety and results for fadraciclib and CYC140, and the effect of continued R&D spending on cash burn.
- Check the timing and variability of Thermo Fisher-related royalty receipts and U.K. R&D tax-credit collections; neither should be assumed to recur at Q1 levels.
- Reconcile share counts: the balance sheet reports 9,993,135 common shares outstanding at March 31, 2022, while the cover page reports 9,994,989 as of May 9, 2022.
- Note a reporting inconsistency in the controls section: it says the evaluation was as of March 31, 2021, although the quarter and surrounding disclosure refer to March 31, 2022.